EML4 and non-small cell lung carcinoma: In contrast to the extensive studies on NPM-ALK, there has been relatively little experimental validation of signalling pathways mediated by EML4-ALK, which has been done mainly through the use of ALK inhibitors in cell lines derived from NSCLC patients and model cell lines expressing recombinant EML4-ALK.